Good post Enos, I have just been fixated on the diagnostic aspect but I see that it does have great value in monitoring. Also, since you would be working with a known set of cancer patients, it could be a lot easier to get approved to monitor cancer than as a general screening test
My approach would still go for approval as a blood chemistry test and let the doctors use it as they want. That way, it could be on the market while trials were run as a cancer monitoring test.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.